HSANZ Free Communications 3: CLL / Basic Science Lymphoid Malignancy
Tracks
HSANZ
| Monday, November 6, 2023 |
| 8:30 AM - 10:00 AM |
| Meeting room 217 |
Details
Kindly sponsored by CSL
Speaker
Prof Constantine Tam
Head, Lymphoma Services
Alfred Health / Monash University
Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
8:30 AM - 8:45 AMBiography
Professor Constantine Tam, MBBS (Hons), MD, is Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University. His research focuses on the use of novel therapies for CLL and related diseases.
Prof Constantine Tam
Head, Lymphoma Services
Alfred Health / Monash University
Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-year follow-up from the FD cohort of the phase 2 CAPTIVATE study
8:45 AM - 9:00 AMBiography
Professor Constantine Tam, MBBS (Hons), MD, is Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University. His research focuses on the use of novel therapies for CLL and related diseases.
Dr Rory Bennett
Fellow
Royal Melbourne Hospital / Peter MacCallum Cancer Centre
Past informs the future: outcomes post allogeneic stem cell transplantation in chronic lymphocytic leukaemia (CLL)
9:00 AM - 9:15 AMBiography
Rory Bennett completed his haematology training in Auckland, New Zealand. He is undertaking a lymphoma and CLL fellowship at the Peter MacCallum Cancer Centre in Melbourne.
Dr Thomas Lew
Haematology Fellow
Peter MacCallum Cancer Centre / Royal Melbourne Hospital
Time-limited venetoclax-rituximab is effective for patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
9:15 AM - 9:30 AMBiography
Haematology advanced trainee and PhD candidate with interest in CLL, lymphoma and discovery of novel therapies
Dr Salvatore Fiorenza
Postdoctoral Research Fellow
The University of Sydney
A novel analysis of histone methylation marks in CART cell clinical products and T cell substrates identifies new transcription factors and associations with product expansion.
9:30 AM - 9:45 AMBiography
Dr Salvatore (Sam) Fiorenza is post-doctoral research fellow at the University of Sydney with Professor Cameron Turtle. He is also a consultant haematologist, medical lead, and deputy director of cell therapy at Epworth HealthCare. He has a research interest in introducing the next generation of cellular immunotherapy for Australian patients.
Associate Professor Jake Shortt
Haematologist
Monash Health
Targeted next generation sequencing (NGS) of circulating tumour DNA (ctDNA) in patients with aggressive B-cell lymphoma - from diagnosis to transformation at relapse.
9:45 AM - 10:00 AMBiography
Prof Shortt is Head of Haematology Research at the School of Clinical Sciences at Monash Health. He leads the 'Blood Cancer Therapeutics Laboratory' at Monash. His research seeks to integrate cancer genomics with drug-target discovery to develop new treatments for poor-risk haematological malignancies.
Chairperson
Mary Anderson
Haematologist
PMC / Royal Melbourne Hospital / Walter and Eliza Hall Institute
Xavier Badoux
Haematologist
St George Hospital
